Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 9/20 | 0.56 |
| ▸ | CTSS | P25774 | 3/20 | 0.53 |
| ▸ | CTSL | P07711 | 2/20 | 0.53 |
| ▸ | CTSB | P07858 | 1/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | CASP9 | P55211 | 1/20 | 0.49 |
| ▸ | MME | P08473 | 1/20 | 0.49 |
| ▸ | ECE1 | P42892 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20819127 | 1.00 | CTSK (0.56) | CTSKCTSSCTSLCTSBFOLH1 | |
| SCHEMBL45470 | 1.00 | CTSK (0.56) | CTSKCTSSCTSLCTSBFOLH1 | |
| SCHEMBL2921260 | 0.90 | FOLH1 (0.59) | CTSKCTSSCTSLCTSBFOLH1 | |
| SCHEMBL677997 | 0.90 | FOLH1 (0.59) | CTSKCTSSCTSLCTSBFOLH1 | |
| SCHEMBL7624700 | 0.90 | FOLH1 (0.59) | CTSKCTSSCTSLCTSBFOLH1 | |
| SCHEMBL3624634 | 0.87 | FOLH1 (0.55) | CTSKCTSSCTSLCTSBFOLH1 | |
| SCHEMBL7286347 | 0.87 | FOLH1 (0.55) | CTSKCTSSCTSLCTSBFOLH1 | |
| SCHEMBL45786 | 0.87 | CASP1 (0.59) | CTSKCTSSCTSLCTSBCASP1 | |
| SCHEMBL3624630 | 0.87 | FOLH1 (0.55) | CTSKCTSSCTSLCTSBFOLH1 | |
| SCHEMBL221391 | 0.87 | KYNU (0.60) | CTSKCTSSCTSLCTSBFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230123729-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | AZEVAN PHARMACEUTICALS INC (US) | 2023-04-20 | — | — | US | disclosed |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | AZEVAN PHARMACEUTICALS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-10953001-B2 | Methods for treating post traumatic stress disorder | AZEVAN PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| EP-3351104-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF INTERMITTENT EXPLOSIVE DISORDER | AZEVAN PHARMACEUTICALS INC (US) | 2020-12-09 | — | — | EP | disclosed |
| EP-3681871-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | Azevan Pharmaceuticals, Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| US-20200102294-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-04-02 | — | — | US | disclosed |
| US-10364236-B2 | Compositions and methods for treating neurodegenerative diseases | AZEVAN PHARMACEUTICALS, INC. (US) | 2019-07-30 | — | — | US | disclosed |
| US-20190099410-A1 | METHODS FOR TREATING POST TRAUMATIC STRESS DISORDER | AZEVAN PHARMACEUTICALS INC (US) | 2019-04-04 | — | — | US | disclosed |
| WO-2019055913-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
| EP-3351104-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF INTERMITTENT EXPLOSIVE DISORDER | Azevan Pharmaceuticals, Inc. (US) | 2018-07-25 | — | — | EP | disclosed |
| US-20180201608-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-07-19 | — | — | US | disclosed |
| US-9987265-B2 | Methods for treating post traumatic stress disorder | AZEVAN PHARMACEUTICALS, INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-9802925-B2 | Compositions and methods for treating neurodegenerative diseases | AZEVAN PHARMACEUTICALS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| EP-3122743-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | Azevan Pharmaceuticals, Inc. (US) | 2017-02-01 | — | — | EP | disclosed |
| WO-2015148962-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | AZEVAN PHARMACEUTICALS, INC. (US) | 2015-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190099410-A1 | METHODS FOR TREATING POST TRAUMATIC STRESS DISORDER | GPX4, CRH, TXN | CTSK 636/4885CTSS 568/4885CTSL 2467/4885 |
| US-20180201608-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | HTT, AVPR2, AVPR1B | CTSK 609/4885CTSS 505/4885CTSL 1667/4885 |
| US-20200102294-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | HTT, AVPR2, AVPR1B | CTSK 609/4885CTSS 505/4885CTSL 1667/4885 |
| US-10953001-B2 | Methods for treating post traumatic stress disorder | GPX4, CRH, TXN | CTSK 636/4885CTSS 568/4885CTSL 2467/4885 |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | HTT, AVPR2, AVPR1B | CTSK 609/4885CTSS 505/4885CTSL 1667/4885 |
| US-20230123729-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | HTT, AVPR2, AVPR1B | CTSK 609/4885CTSS 505/4885CTSL 1667/4885 |
| US-10364236-B2 | Compositions and methods for treating neurodegenerative diseases | HTT, AVPR2, AVPR1B | CTSK 609/4885CTSS 505/4885CTSL 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.